Peripheral venous blood was obtained from 4 DENV‐acute patients and 1 late‐acute phase disease (with 22 days’ illness), 4 ZIKV‐acute patients and, 7 DENV/ZIKV coinfected acute patients. As shown in Table 1, patient 2 confirmed DENV‐1 infection using Simplexa™ Dengue Real Time RT‐PCR (Ct, Cycle threshold value = 34.6) even after 22 days of onset of symptoms. All four matched healthy donors were negative for DENV IgM, positive for DENV IgG, and negative for RT‐PCR ZIKV, so they were referred here as DENV‐exposed donors. Thirteen patients (76.5%) had dengue during their lifetime, presumed by the positivity for DENV IgG, in which 5 individuals were from DENV group, 3 from ZIKV, and 5 from DENV/ZIKV coinfection group. Most of DENV‐ or DENV/ZIKV patients showed a mild clinical form (non‐warning signals or NWS) and no fatal cases were observed among the cohort studied. In general, symptoms and signs caused by these viruses were similar among the studied groups, and the patients presented typical symptoms such as fever, rash, arthralgia, myalgia, fatigue, headache, and conjunctival hyperemia. No differences were observed in age, gender distribution or days of disease comparing all groups. Similarly, no differences were seen for platelets, leukocytes, and lymphocytes counts among groups. The serotype DENV‐1 was predominant among DENV‐ or DENV/ZIKV‐coinfected patients (80%). Finally, all studied samples were also negative for CHIKV diagnosis. The characteristics of all acute patients are detailed in Table 1.